The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer


YERLİKAYA A., Kanbur E., Stanley B. A., TÜMER E.

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol.21, no.1, pp.20-32, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 21 Issue: 1
  • Publication Date: 2021
  • Doi Number: 10.2174/1871520620666200811114159
  • Journal Name: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Biotechnology Research Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE
  • Page Numbers: pp.20-32
  • Bursa Uludag University Affiliated: Yes

Abstract

Background: The ubiquitin-proteasome pathway is involved in almost all cellular processes (cell cycle, gene transcription and translation, cell survival and apoptosis, cell metabolism and protein quality control) mainly through the specific degradation of the majority of intracellular proteins (>80%) or partial processing of transcription factors (e.g., NF-kappa B). A growing amount of evidence now indicates that epigenetic changes are also regulated by the ubiquitin-proteasome pathway. Recent studies indicate that epigenetic regulations are equally crucial for almost all biological processes as well as for pathological conditions such as tumorigenesis, as compared to non-epigenetic control mechanisms (i.e., genetic alterations or classical signal transduction pathways).